Results 141 to 150 of about 48,696 (305)
Journal of Evaluation in Clinical Practice, Volume 31, Issue 7, October 2025.ABSTRACT Background Pharmacological therapy in older persons is inherently complex due to the interplay of age‐related physiological changes, multimorbidity, and polypharmacy. These factors increase the vulnerability of elderly patients to drug interactions and adverse drug reactions.
N. N. Ngcobo
wiley +1 more source
PLoS ONE, 2015 IntroductionThe fast, precise, and accurate measurement of the new generation of oral anticoagulants such as dabigatran and rivaroxaban in patients' plasma my provide important information in different clinical circumstances such as in the case of ...
Joachim Kuhn +7 more
doaj +1 more source
Idarucizumab for Dabigatran Reversal in the Management of Patients With Gastrointestinal Bleeding
Circulation, 2019 Background: Although dabigatran has a favorable risk-benefit profile compared with vitamin K antagonist therapy for venous thromboembolism and nonvalvular atrial fibrillation, major bleeding events, including gastrointestinal (GI) bleeding, may occur ...
S. J. van der Wall +9 more
semanticscholar +1 more source
, 2015 The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J +2 more
core +1 more source
Liver International, Volume 45, Issue 10, October 2025.ABSTRACT Background and Aims Advances in artificial intelligence, particularly large language models (LLMs), hold promise for transforming chronic disease management such as Hepatitis C Virus (HCV) infection. This study evaluates the impact of retrieval‐augmented generation (RAG) and supervised fine‐tuning (SFT) on both open‐ended question answering ...
Mauro Giuffrè +9 more
wiley +1 more source
Drugs - Real World Outcomes, 2019 Introduction The new user cohort design is widely used to assess the effects of a new drug, such as dabigatran, but inherently excludes some users due to prior use of the comparator drug, for example warfarin.
Hui-Min Diana Lin +5 more
doaj +1 more source
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +2 more sources
Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis [PDF]
, 2007 Wolfgang Wienen +4 more
openalex +1 more source
Therapeutic Advances in Neurological Disorders, 2015 Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris +3 more
doaj +1 more source
Dabigatran: oral prophylaxis for venous thromboembolism [PDF]
, 2008 Steve Chaplin, Simon P. Frostick
openalex +1 more source